Conversely, Mcl-1 knock-down in PS-R cells significantly sensitized MM cells to the proteasome inhibitors bortezomib and carfilzomib (cfz; P < 0.01 in each case; Figure 1D). This evidence concerns the gene MCL1 and Miyoshi myopathy.